VKTX - Why Eli Lilly And Rival Novo Nordisk Won't Be Troubled By Viking's Latest Weight Loss Data

2024-03-31 02:10:00 ET

Summary

• Eli Lilly and Novo Nordisk have created what Wall Street believes will be the biggest ever pharmaceutical market with its miraculous weight loss drugs.
• Novo Nordisk's Ozempic and Wegovy, as well as Eli Lilly's Mounjaro and Zepbound, have already generated billions of dollars in revenue but this may be the tip of the iceberg.
• Viking Therapeutics' VK2735 has emerged as a strong contender in the GLP-1 drug market, with promising weight loss results in clinical studies.
• While Viking's data is immature and based on small patients samples, however, Lilly and Novo's vast experience and established infrastructure mean they remain well ahead of the competition.
• In fact, Lilly and Novo's next-generation drug looks better than any other companies, and as crazy as it may sound, it may be that a trillion dollar market cap valuation beckons.

Investment Overview- Background To Stunning Rise Of GLP-1 Analogue Drug Class

Doubtless, readers will be familiar with the Wegovy / Zepbound, Ozempic / Mounjaro, tirzepatide / semaglutide "miracle" weight loss story by now - but to recap:

Semaglutide is a glucagon-like peptide-1 receptor agonist, or "GLP-1" agonist / analogue developed by Danish Pharma Novo Nordisk ( NVO ). These types of drugs have been used for many years to treat type 2 diabetes, as they prompt the body to produce more insulin....

For further details see: